TriSalus Life Sciences
TLSI
10 hedge funds and large institutions have $18.3M invested in TriSalus Life Sciences in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
81.28% more ownership
Funds ownership: 6.88% → 88.16% (+81%)
11% more funds holding
Funds holding: 9 → 10 (+1)
6% more capital invested
Capital invested by funds: $17.3M → $18.3M (+$1.01M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCWM
Graham Capital Wealth Management
Washington D.c.,
District of Columbia
|
+$69.9K |
| 2 |
CS
Clear Street
New York
|
+$659 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$40.6K |
| 2 |
VF
Virtu Financial
New York
|
-$20K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$19.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MF
1
Magnetar Financial
Evanston,
Illinois
| $11.8M | – | – | – |
|
|
DFCM
2
Dark Forest Capital Management
San Juan,
Puerto Rico
| $3.56M | – | – | – |
|
|
SIA
3
SkyView Investment Advisors
Shrewsbury,
New Jersey
| $1.54M | – | – | – |
|
|
GCWM
4
Graham Capital Wealth Management
Washington D.c.,
District of Columbia
| $705K | +$69.9K | +6,893 | New |
|
|
MC
5
Meteora Capital
Boca Raton,
Florida
| $246K | – | – | – |
|
6
Geode Capital Management
Boston,
Massachusetts
| $176K | – | – | – |
|
|
BFM
7
Boothbay Fund Management
New York
| $164K | – | – | – |
|
|
VF
8
Virtu Financial
New York
| $106K | -$20K | -1,973 | -16% |
|
|
9
UBS Group
Zurich,
Switzerland
| $1.15K | -$19.7K | -1,947 | -95% |
|
|
CS
10
Clear Street
New York
| $663 | +$659 | +65 | New |
|
|
11
Morgan Stanley
New York
| – | -$40.6K | -4,050 | Closed |
|
TLSI Hedge Fund Activity: Q1 2023 in Review
10 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q1 2023, worth a combined $18.3M — up 5.9% from $17.3M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TLSI positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Graham Capital Wealth Management, opening a new position worth an estimated $69.9K. The largest seller was Morgan Stanley, exiting entirely with an estimated $40.6K sold.
- 10 institutional investors held TriSalus Life Sciences (TLSI) as of Q1 2023, up from 9 in Q4 2022.
- Funds reported $18.3M of TriSalus Life Sciences stock for Q1 2023, up 5.9% quarter-over-quarter.
- 2 funds opened new TriSalus Life Sciences positions in Q1 2023 and 1 closed out, a net change of +1 holder.
- The largest TriSalus Life Sciences buyer in Q1 2023 was Graham Capital Wealth Management, an estimated $69.9K added.
- The largest TriSalus Life Sciences seller in Q1 2023 was Morgan Stanley, an estimated $40.6K sold.
Based on aggregated 13F filings for Q1 2023.